Skip to content
Company Analysis

GSK plc GSK

A comprehensive view of key metrics, scores, and financial health for GSK plc

Overview of GSK plc

GSK NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Large Cap
GSK plc (GSK), is a Large Cap company, in the Drug Manufacturers - General industry, last closed at $49.13, about 2.8% undervalued vs fair value, +4.3% 1Y return, ranked 567/1145 in sector.
Metrics P/E 13.1× Rev Growth 4.1% ROE 38.1% Gross Margin 72.4% Div Yield 3.49%
USD 49.13
-0.77%
(Delayed)
• Vol 90d: 26.2%
52-Week Range
Market Cap
$98.15B
Enterprise Value
$117.89B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Fair
Profitability
Weak
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.gsk.com
HQ London
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$46
$51
$55
Current: $49.13 +3% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
GBP 32.7B
4.1%%
Gross Profit
GBP 23.6B
5.9%%
R&D Expense
GBP 7.5B
17.6%%
Operating Income (EBIT)
GBP 8.1B
96.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
95.7%
Good

Good cash conversion

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

GBP 3.9B
82.9% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
0/3
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating GSK plc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
55
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • ROIC Sustainably Above Peers ROIC at 84.2th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Operating Leverage in Effect Operating leverage is evident (score 0.72), with margins expanding over time.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.26), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
61
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing GSK's balance between Growth (31.9%), Profitability (46.6%), and Safety (21.6%). Growth 32% Safety 22% Profitability 47%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

56th percentile vs peers
57
Key Signals
EPS Growth YoY 1.23 84p Rev Growth YoY 4.1% 50p Revenue CAGR 3Y 3.7% 50p TSR 50.1% 83p EPS CAGR 3Y -27.6% 25p
Strengths
  • EPS Growth YoY in top 20% of peers (1.23, 84th percentile)
  • Interest Coverage Ratio in top 20% of peers (11.77, 86th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • TSR in top 20% of peers (50.1%, 83th percentile)
Risks

No significant risks identified for this axis.

Profitability

82th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

38th percentile vs peers
38
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for GSK plc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$50.53
- - -
+2.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000